A Study of AZD0120 in Autoimmune Diseases
Phase 1
27
about 2.2 years
18–75
8 sites in AZ, CA, IL +5
What this study is about
Researchers are testing a treatment called AZD0120 for people with autoimmune diseases like idiopathic inflammatory myopathies, rheumatoid arthritis, or systemic sclerosis. The trial will evaluate the safety and tolerability of this treatment in adults.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive AZD0120
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of participants and severity of dose limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs)
Secondary: Cellular Kinetics - AUC, Cellular Kinetics - Cmax, Cellular Kinetics - Tmax, Change from baseline in modified Rodnan Skin Score (mRSS). The mRSS is a measure of skin thickness with a range of 0-51 with higher scores indicating more severe disease., Change from baseline in the Disease Activity Score (DAS) 28-C-reactive protein (CRP). The DAS28-CRP is a measure from 0-10 with higher scores indicating greater disease activity., Change from baseline in the total improvement score (TIS). The TIS ranges from 0-100 with higher scores indicating greater improvement.
Immune